1. Home
  2. SGA vs ACET Comparison

SGA vs ACET Comparison

Compare SGA & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saga Communications Inc. (FL)

SGA

Saga Communications Inc. (FL)

HOLD

Current Price

$11.12

Market Cap

73.7M

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$6.94

Market Cap

69.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGA
ACET
Founded
1986
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.7M
69.6M
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
SGA
ACET
Price
$11.12
$6.94
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$56.00
AVG Volume (30 Days)
8.4K
111.8K
Earning Date
03-12-2026
03-12-2026
Dividend Yield
8.94%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$124,829,000.00
N/A
Revenue This Year
$6.74
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.65
N/A
52 Week Low
$10.68
$0.45
52 Week High
$14.27
$9.05

Technical Indicators

Market Signals
Indicator
SGA
ACET
Relative Strength Index (RSI) 42.76 45.55
Support Level $10.68 $6.54
Resistance Level $12.60 $8.34
Average True Range (ATR) 0.22 0.44
MACD -0.05 -0.06
Stochastic Oscillator 23.63 17.94

Price Performance

Historical Comparison
SGA
ACET

About SGA Saga Communications Inc. (FL)

Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: